Back to News
Market Impact: 0.2
Femasys Doubles Enrollment Sites For FemBloc Pivotal Study; Stock Down
Source: Nasdaq
Healthcare & Biotech
Femasys doubled the number of actively enrolling U.S. sites in its FINALE pivotal trial of FemBloc to 12. The update indicates expanded trial enrollment but provides no enrollment totals or results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
FEMY0.55
More News
- Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
- Supernus Pharmaceuticals stock hits 52-week low at 40.5 USD
- Liquidia shares surge 25% as settlement ends United Therapeutics litigation
- Top biotechnology stock pick from Guggenheim
- Needham raises Starling Oncology stock price target on growth outlook
- Stifel raises IQVIA stock price target on improving market backdrop
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Run Cost-Controlled Financial Research in AllMind Agent Studio
- State of Public Markets, June 2026: Higher for Longer Meets the AI Supercycle